** Shares of drug distributor Cencora COR.N rise 5.7% to $307.50
** Co raises annual adj.profit forecast on strong demand for costly specialty medicines and weight-loss drugs
** Expects 2025 adj.profit to be between $15.70 and $15.95 per share, up from its previous expectation of $15.30 to $15.60 per share
** Q2 revenue at its U.S. healthcare business came in at $68.3 billion, up 11.4% from a year earlier
** Reports Q2 adj.profit of $4.42 per share, beating analysts' estimates of $4.11 per share, as per data compiled by LSEG
** "The fact that COR has now increased guidance 4x so far in FY25 (this is only the second fiscal quarter report) shows underlying confidence in the business as well"- brokerage Leerink Partners
** Including session moves, stock up 36.6% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。